Literature DB >> 12719441

Different effect of antihypertensive drugs on conduit artery endothelial function.

Lorenzo Ghiadoni1, Armando Magagna, Daniele Versari, Isabella Kardasz, Yale Huang, Stefano Taddei, Antonio Salvetti.   

Abstract

To compare the effect of antihypertensive drugs on endothelium-dependent vasodilation in the peripheral conduit arteries of patients with essential hypertension, in a prospective, randomized, parallel group study, endothelial function was assessed in 168 hypertensive patients before and after 6-month treatment with randomly assigned nifedipine GITS (30 to 60 mg, n=28), amlodipine (5 to 10 mg, n=28), atenolol (50 to 100 mg, n=29), nebivolol (5 to 10 mg, n=28), telmisartan (80 to 160 mg, n=29), and perindopril (2 to 4 mg, n=28). If necessary, hydrochlorothiazide (25 mg) was added to each compound. We evaluated brachial artery flow-mediated, endothelium-dependent dilation (high-resolution ultrasound) compared with endothelium-independent response to glyceryl trinitrate (25 microg/s). Brachial artery diameter was measured by automatic computerized analysis. Forty healthy subjects were evaluated as a control group. Oxidative stress production was evaluated by measuring plasma malondialdehyde and plasma lipoperoxides; plasma antioxidant capacity was assessed as ferric-reducing antioxidant power. Hypertensive patients showed a significantly (P<0.01) lower flow-mediated dilation (5.2+/-1.9%) as compared with healthy control subjects (7.1+/-2.6%). Response to glyceryl trinitrate was similar in control subjects and patients. At baseline, blood pressure, diameter, flow-mediated dilation, and response to glyceryl trinitrate were similar in the different treatment groups. All treatments similarly reduced blood pressure, but only perindopril increased flow mediated dilation (from 5.1+/-2 to 6.4+/-2.4%; P<0.01) without modifying the response to glyceryl trinitrate. Perindopril but also telmisartan nifedipine and amlodipine reduced oxidative stress and increased plasma antioxidant capacity. In patients with essential hypertension, ACE inhibitors appear to be the only compounds able to improve conduit artery endothelium-dependent vasodilation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719441     DOI: 10.1161/01.HYP.0000070956.57418.22

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  79 in total

Review 1.  Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Authors:  Benjamin J Powers; Remy R Coeytaux; Rowena J Dolor; Vic Hasselblad; Uptal D Patel; William S Yancy; Rebecca N Gray; R Julian Irvine; Amy S Kendrick; Gillian D Sanders
Journal:  J Gen Intern Med       Date:  2011-12-07       Impact factor: 5.128

Review 2.  Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease.

Authors:  Richard A Cohen; XiaoYong Tong
Journal:  J Cardiovasc Pharmacol       Date:  2010-04       Impact factor: 3.105

Review 3.  Reactive oxygen species and vascular remodelling in hypertension: still alive.

Authors:  Shaoping Xu; Rhian M Touyz
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

4.  Effects of antihypertensive treatment on endothelial function.

Authors:  Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

5.  Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

Authors:  Kwang Kon Koh; Michael J Quon; Seung Hwan Han; Yonghee Lee; Soo Jin Kim; Yesl Koh; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2008-12-06       Impact factor: 4.164

Review 6.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

7.  Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Authors:  Fabio Mangiacapra; Iginio Colaiori; Elisabetta Ricottini; Francesco Balducci; Antonio Creta; Chiara Demartini; Giorgio Minotti; Germano Di Sciascio
Journal:  Clin Res Cardiol       Date:  2016-08-12       Impact factor: 5.460

Review 8.  Reactive oxygen species in vascular biology: implications in hypertension.

Authors:  R M Touyz; E L Schiffrin
Journal:  Histochem Cell Biol       Date:  2004-08-26       Impact factor: 4.304

9.  Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.

Authors:  K Swaminathan; J Davies; J George; N S Rajendra; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2008-03-18       Impact factor: 10.122

Review 10.  Management of hypertension in the elderly patient.

Authors:  Gordon Stewart Stokes
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.